Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy

Addiction

Volumn 104, Issue 4, 2009, Pages 630-640

  Schäfer, Arne ^a   Wittchen, Hans Ulrich ^b   Backmund, Markus ^c   Soyka, Michael ^d   Gölz, Jörg ^e   Siegert, Jens ^b   Schäfer, Martin ^f,g   Tretter, Felix ^h   Kraus, Michael R ⁱ  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Institut fur Suchtmedizin und Adipositas   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Praxiszentrum Kaiserdamm   (Germany)

^f Klinken Essen Mitte   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h KLINIKUM MÜNCHEN OST   (Germany)

ⁱ Abteilung Gynäkologie und Geburtshilfe   (Germany)

Author keywords

Antiviral treatment; Buprenorphine; Depression; Hepatitis C; Interferon ; Methadone; Psychopathology; Quality of life; Substitution

Indexed keywords

ALPHA INTERFERON; BUPRENORPHINE; METHADONE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BRIEF SYMPTOM INVENTORY; CLINICAL TRIAL; COHORT ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; GERMANY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; SLEEP DISORDER; SOMATIZATION; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; BUPRENORPHINE; FEMALE; GERMANY; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LONGITUDINAL STUDIES; MALE; METHADONE; NARCOTIC ANTAGONISTS; QUALITY OF LIFE; QUESTIONNAIRES; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 62649168624     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02509.x     Document Type: Article

References (49)

1. Wittchen H. U., Apelt S. M., Soyka M., Gastpar M., Backmund M., Golz J. et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend 2008 95 : 245 57.
2. Kraus M. R., Schafer A., Csef H., Scheurlen M., Faller H. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000 41 : 377 84.
3. Kraus M. R., Schafer A., Faller H., Csef H., Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003 64 : 708 14.
4. Alter M. J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006 44 : S6 9.
5. Heathcote J., Main J. Treatment of hepatitis C. J Viral Hepatol 2005 12 : 223 35.
6. Shepard C. W., Finelli L., Alter M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005 5 : 558 67.
7. Alter M. J. Epidemiology of hepatitis C. Hepatology 1997 26 : 62S 65S.
8. Crofts N., Nigro L., Oman K., Stevenson E., Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997 92 : 999 1005.
9. Crofts N., Jolley D., Kaldor J., van Beek I., Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Commun Health 1997 51 : 692 7.
10. Diamantis I., Bassetti S., Erb P., Ladewig D., Gyr K., Battegay M. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997 26 : 794 7.
11. Dinwiddie S. H., Shicker L., Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003 160 : 172 4.
12. Backmund M., Meyer K., Wachtler M., Eichenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 2003 18 : 563 8.
13. Manns M. P., McHutchison J. G., Gordon S. C., Rustgi V. K., Shiffman M., Reindollar R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
14. Fried M. W., Shiffman M. L., Reddy K. R., Smith C., Marinos G., Goncales F. L. Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
15. Vocci F. J., Acri J., Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005 162 : 1432 40.
16. Cozzolino E., Guglielmino L., Vigezzi P., Marzorati P., Silenzio R., De Chiara M. et al. Buprenorphine treatment: a three-year prospective study in opioid-addicted patients of a public out-patient addiction center in Milan. Am J Addict 2006 15 : 246 51.
17. Schaefer M., Heinz A., Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004 99 : 1167 75.
18. Loftis J. M., Matthews A. M., Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs 2006 66 : 155 74.
19. Schaefer M., Schmidt F., Folwaczny C., Lorenz R. Martin G., Schindlbeck N. et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003 37 : 443 51.
20. Schaefer M., Hinzpeter A., Mohmand A., Janssen G., Pich M., Schwaiger M. et al. Hepatitis C treatment in 'difficult-to-treat' psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007 46 : 991 8.
21. Verrando R., Robaeys G., Mathei C., Buntinx F. Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Acta Gastroenterol Belg 2005 68 : 81 5.
22. Robaeys G., Van Vlierberghe H., Mathei C., Van Ranst M., Bruckers L., Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006 18 : 159 66.
23. Wittchen H. U., Apelt S. M., Buhringer G., Gastpar M., Backmund M., Golz J. et al. Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study. Int J Methods Psychiatr Res 2005 14 : 14 28.
24. Wittchen H. U., Apelt S. M., Christl B., Hagenau K., Groß A., Klotsche J. et al. Die Versorgungspraxis der Substitutionstherapie Opiatabhängiger (COBRA) [The practice of supply in the substitution therapy for opiate addicts (COBRA)]. Suchtmed Forsch Praxis 2004 6 : 80 7.
25. Gsellhofer B., Küfner H., Vogt M., Weiler D. European Addiction Severity Index - EuropASI. Manual für Training und Durchführung [Manual for Training and Execution]. Stuttgart : Schneider Verlag 1999.
26. Franke G. H. BSI - Brief Symptom Inventory von L. R. Derogatis (Kurzform der SCL-90-R) - Deutsche Version. Göttingen : Beltz 2000.
27. Derogatis L. R., Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983 13 : 595 605.
28. Wittchen H. U. Reliability and validity studies of the WHO - Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res 1994 28 : 57 84.
29. Wittchen H. U., Lachner G., Wunderlich U., Pfister H. Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol 1998 33 : 568 78.
30. Greiner W., Weijnen T., Nieuwenhuizen M., Oppe S., Badia X., Busschbach J. et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 2003 4 : 222 31.
31. Brooks R., Rabin R., de Charro F. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. Amsterdam : Kluwer Academic Publishers 2003.
32. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990 16 : 199 208.
33. Guy W. Clinical global impressions scale. In : National Institute of Mental Health, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD : National Institute of Mental Health 1976, p. 221 7.
34. World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision, 2nd edn. Geneva : World Health Organization 1992.
35. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva : World Health Organization 1992.
36. Judge G. G., Griffiths W. E., Hill R. C., Lütkepohl H., Tsoung-Chao L. The Theory and Practice of Econometrics. New York : Wiley 1985.
37. Choi J. W., McHugh R. B. A reduction factor in goodness-of-fit and independence tests for clustered and weighted observations. Biometrics 1989 45 : 979 96.
38. Huber P. J. The behavior of maximum likelihood estimates under non-standard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Berkeley, CA : University of California Press 1967.
39. White H. Maximum likelihood estimation of misspecified models. Econometrica 1982 50 : 1 25.
40. Royall R. M. Model robust confidence intervals using maximum likelihood estimators. Int Stat Rev 1986 56 : 221 6.
41. StataCorp. Stata Release 10.0. College Station : StataCorp 2007.
42. Kraus M. R., Schafer A., Csef H., Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005 11 : 1769 74.
43. Bruggmann P., Seidenberg A., Meili D., Kesseli B., Huber M. Hepatitis-C- und HIV-Prävalenz sowie antiretrovirale Therapie in einem niederschwelligen Opiatsubstitutionsprogramm - Eine Querschnittsanalyse [Hepatitis C- and HIV prevalence and antiretroviral therapy in a low threshold opiate maintenance program - a cross-sectional analysis]. Suchttherapie 2005 6 : 78 82.
44. Butt A. A., Wagener M., Shakil A. O., Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepatol 2005 12 : 81 5.
45. Schaefer M., Schwaiger M., Garkisch A. S., Pich M., Hinzpeter A., Uebelhack R. et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005 42 : 793 8.
46. Foster G. R., Goldin R. D., Thomas H. C. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998 27 : 209 12.
47. Sulkowski M., Wright T., Rossi S., Arora S., Lamb M., Wang K. et al. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther 2005 77 : 214 24.
48. Mauss S., Berger F., Goelz J., Jacob B., Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004 40 : 120 4.
49. Sylvestre D. L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002 67 : 117 23.